GSK raised its full-year 2025 forecast on Wednesday, citing strong sales of its specialty medicines and vaccines and recent drug approvals, including for its cancer treatment Blenrep.
The British drugmaker now expects 2025 turnover to grow between 6% and 7% at constant exchange rates, up from a previous range of 3% to 5%, the company said.
Core earnings per share are now projected to increase by 10% to 12%, compared to the prior forecast of 6% to 8%.
The upgraded outlook follows a strong third quarter, where total sales rose 8% at constant exchange rates to 8.5 billion British Pounds, and core earnings per share increased by 14% to 55.0 pence.
Performance was driven by the Specialty Medicines division, where sales grew 16% to 3.4 billion British Pounds, boosted by its HIV, oncology, and immunology drugs.
Vaccines sales increased 2% to 2.7 billion British Pounds, led by its shingles vaccine, Shingrix.
The company highlighted four major product approvals so far this year, including the recent U.S. approval for Blenrep to treat a type of blood cancer called multiple myeloma.
"GSK's momentum continues with another quarter of strong performance, supporting upgraded guidance for 2025, and positioning us well for 2026 and achieving our longer-term growth outlooks," said CEO Emma Walmsley in a statement.
"Sales grew in all areas, with particularly strong performances in Specialty Medicines driven by double-digit growth in Respiratory Inflammation & Immunology, Oncology and HIV."
More from this issuer
Related coverage
GSK said Thursday its cancer drug Blenrep won U.S. approval to treat adults with multiple myeloma that has returned or stopped responding to treatment, overcoming an earlier negative recommendation from a regulatory advisory panel.
GSK announced positive late-stage trial results for a new, low-carbon version of its widely used Ventolin asthma inhaler.
GSK and partner Alector said Tuesday their experimental drug for a rare form of dementia failed to meet its main goal in a late-stage trial.
GSK and Spero Therapeutics on Tuesday announced positive late-stage trial results for their investigational oral antibiotic, tebipenem HBr, for treating complicated urinary tract infections (cUTIs).